Voyager Therapeutics Intrinsic Value Calculator – VOYAGER THERAPEUTICS Reports Positive Financial Results for 2nd Quarter of FY2023

August 7, 2023

☀️Earnings Overview

VOYAGER THERAPEUTICS ($NASDAQ:VYGR) reported their second quarter financial results for FY2023 on June 30, 2023. Their total revenue rose to USD 4.8 million in comparison to the previous year’s USD 0.7 million; however, their net income declined to USD -22.2 million from USD -19.1 million in the same period of the previous year.

Stock Price

The stock opened at $8.8 and closed at $9.3, up 3.4% from its prior closing price of $9.0. This jump in the price of the stock is a testament to the company‚Äôs strong performance in the quarter. This indicates that VOYAGER THERAPEUTICS is able to produce their products at a more efficient rate than before. Overall, these positive financial results show that VOYAGER THERAPEUTICS is on the right track and in a good position for further growth and success in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Voyager Therapeutics. More…

    Total Revenues Net Income Net Margin
    194.87 95.83 49.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Voyager Therapeutics. More…

    Operations Investing Financing
    94.28 38.62 33.15
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Voyager Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    315.54 116.51 4.57
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Voyager Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    25.0% 44.8%
    FCF Margin ROE ROA
    46.9% 26.2% 17.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Voyager Therapeutics Intrinsic Value Calculator

    At GoodWhale, we conducted an analysis of VOYAGER THERAPEUTICS‘s wellbeing. We calculated the intrinsic value of its shares to be around $16.5 using our proprietary Valuation Line. This is significantly higher than the current price of $9.3 at which the stock is currently trading. This means that VOYAGER THERAPEUTICS is currently undervalued by 43.5%. Our analysis suggests a compelling opportunity to invest in VOYAGER THERAPEUTICS at this time. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    The competition between Voyager Therapeutics Inc and its competitors is fierce. Geovax Labs Inc, RAPT Therapeutics Inc, and Ocugen Inc are all vying for a piece of the pie, and each company has its own unique strengths and weaknesses. It will be interesting to see how this competition plays out in the coming years.

    – Geovax Labs Inc ($NASDAQ:GOVX)

    Geovax Labs Inc is a biotechnology company that focuses on the development and commercialization of vaccines. The company’s main products are HIV/AIDS vaccines. Geovax’s market cap is 20.91 million as of 2022 and its ROE is -103.82%. The company has been facing financial difficulties in recent years and has been working to improve its financial situation.

    – RAPT Therapeutics Inc ($NASDAQ:RAPT)

    RAPT Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of small molecule drugs to treat cancer and other serious diseases. Its lead candidate, RPT-100, is a first-in-class, selective inhibitor of JAK1/2. The company’s other product candidates include RPT-101, a dual inhibitor of JAK1/2 and JAK3, and RPT-102, an inhibitor of JAK1. RAPT Therapeutics is headquartered in San Francisco, California.

    – Ocugen Inc ($NASDAQ:OCGN)

    Ocugen Inc is a pharmaceutical company that focuses on the development and commercialization of treatments for orphan diseases. The company has a market capitalization of $350.84 million and a return on equity of -51.6%. The company’s products include treatments for retinitis pigmentosa, glaucoma, and diabetic retinopathy.

    Summary

    VOYAGER THERAPEUTICS reported their financial results for the second quarter of FY2023, with total revenue increasing to USD 4.8 million compared to the previous year’s USD 0.7 million. Despite this, their net income decreased to USD -22.2 million from USD -19.1 million in the same period. Nevertheless, the stock price for VOYAGER THERAPEUTICS moved up the same day. With such promising revenue growth and potential for improved profitability, investors may want to consider investing in VOYAGER THERAPEUTICS as they continue to build on their success and develop new treatments and therapies.

    Recent Posts

    Leave a Comment